- May 18, 2024
- 232
- 24
Recently, there's been growing debate in the fitness and medical communities about GLP-1 receptor agonists like Ozempic® and Mounjaro®, particularly concerning their potential association with muscle loss. This topic has generated significant interest and concern among both healthcare professionals and patients alike.
To provide clarity on this important issue, I've conducted an in-depth review of the latest clinical research and real-world evidence. My analysis examines:
As research in this area continues to evolve, I'll be updating this analysis with new findings. In the meantime, I welcome discussion and questions from readers who want to better understand this complex topic.

To provide clarity on this important issue, I've conducted an in-depth review of the latest clinical research and real-world evidence. My analysis examines:
- The mechanisms behind potential muscle loss
- Comparative data between these medications
- Strategies for muscle preservation during treatment
- Expert recommendations for mitigating risks
As research in this area continues to evolve, I'll be updating this analysis with new findings. In the meantime, I welcome discussion and questions from readers who want to better understand this complex topic.

